OS Therapies Incorporated
AMEX:OSTX · New York Stock Exchange American
-$0.01 today
Vol 0.20M · Avg 0.70M
Income Statement
Follow revenue through to earnings
Review sales, margins, expenses, and profit trends to see what is actually driving reported earnings over time.
Stock Ticker Earnings Waterfall
AMEX:OSTX · Revenue to Net Income
Key Ratios
Analysis
$0 of revenue converted into -$35.3M of net income for the selected period. Gross margin is 0.0% and net margin is 0.0%, showing how much revenue survives after costs and taxes. EPS is $-1.07, tying the income statement back to per-share earnings.
Income Statement
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $809.6M | $921.6M | $731.2M |
| Cost of Revenue | $363.1K +12960.6% | $2.8K -34.1% | $4.2K +424.2% | $805 -99.9% | $1.2M | $725.6M | $804.0M | $882.4M |
| Gross Profit | -$363.1K -12960.6% | -$2.8K +34.1% | -$4.2K -424.2% | -$805 +99.9% | -$1.2M | $8.9B | $7.6B | $6.2B |
| Gross Margin | — | — | — | — | — | 9.8% | 28.9% | 38.3% |
| Research & Development | $16.4B +576737.4% | $2.8M -11.8% | $3.2M -2.3% | $3.3M +51.4% | $2.2M | $983.2M | $1.3B | $490.4M |
| Selling, General & Admin | $12.3B +310482.2% | $4.0M +254.7% | $1.1M -2.9% | $1.2M -23.3% | $1.5M | $620.6M | $923.0M | -$1.5B |
| Operating Expenses | $28.3M +316.1% | $6.8M +56.8% | $4.3M -2.3% | $4.4M +20.9% | $3.7M | $5.3B | $7.0B | $8.7B |
| Depreciation & Amortization | $363.1K +12960.6% | $2.8K -34.1% | $4.2K +424.2% | $805 +0.0% | $805 | $374.2M | $1.2B | $631.8M |
| EBITDA | -$28.4M -315.8% | -$6.8M -57.4% | -$4.3M +2.4% | -$4.4M +8.1% | -$4.8M | -$15.2B | $6.8B | $9.3B |
| EBITDA Margin | — | — | — | — | — | 5.6% | 46.3% | 42.0% |
| Operating Income | -$28.7M -321.3% | -$6.8M -56.9% | -$4.3M +2.3% | -$4.4M +8.1% | -$4.8M | $12.3B | $14.0B | -$15.7B |
| Operating Margin | — | — | — | — | — | 16.6% | 24.1% | 22.0% |
| Interest Income | $249 | $0 | $0 | $0 | $0 | -$1.5B | -$1.6B | $405.0M |
| Interest Expense | $0 -100.0% | $2.1M -40.5% | $3.4M +90.7% | $1.8M -30.0% | $2.6M | $1.1B | $1.0B | $1.2B |
| Other Income / Expenses | -$48.1K +97.7% | -$2.1M +40.0% | -$3.4M -90.7% | -$1.8M +30.0% | -$2.6M | -$1.5B | $1.4B | $1.2B |
| Income Before Tax | -$28.8M -223.7% | -$8.9M -14.0% | -$7.8M -24.6% | -$6.3M +15.7% | -$7.4M | $3.3B | $4.9B | $3.6B |
| Pre-Tax Margin | — | — | — | — | — | 20.8% | 18.7% | 26.2% |
| Income Tax Expense | $0 | $0 | $0 | $0 | $0 | $1.3B | -$1.6B | $745.2M |
| Net Income | -$28.8M -223.7% | -$8.9M -14.0% | -$7.8M -24.6% | -$6.3M +15.7% | -$7.4M | $4.9B | $4.8B | $4.7B |
| Net Margin | — | — | — | — | — | 12.4% | 17.5% | 22.5% |
| EPS (Basic) | -$1 -88.5% | -$1 -33.3% | -$0 -39.3% | -$0 +15.2% | -$0 | $400.8M | $703.2M | $1.3B |
| EPS (Diluted) | -$1 -88.5% | -$1 -33.3% | -$0 -39.3% | -$0 +15.2% | -$0 | $766.2M | $609.4M | $452.6M |
| Weighted Avg Shares | $29.3M +40.2% | $20.9M +4.1% | $20.0M -13.2% | $23.1M +0.0% | $23.1M | $757.8M | $925.8M | $1.1B |
| Weighted Avg Shares (Diluted) | $29.3M +40.2% | $20.9M +4.1% | $20.0M -13.2% | $23.1M +0.0% | $23.1M | $1.2B | $924.4M | $678.0M |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
Adagene Inc.
NASDAQ:ADAG
$134.41M
Equillium, Inc.
NASDAQ:EQ
$99.82M
Spruce Biosciences, Inc.
NASDAQ:SPRB
$71.19M
NRx Pharmaceuticals, Inc.
NASDAQ:NRXP
$66.38M
MiNK Therapeutics, Inc.
NASDAQ:INKT
$59.88M
Coeptis Therapeutics, Inc.
COEP
$57.63M
Outlook Therapeutics, Inc.
NASDAQ:OTLK
$50.19M
CervoMed Inc.
CRVO
$22.68M
Werewolf Therapeutics, Inc.
HOWL
$18.52M
IO Biotech, Inc.
IOBT
$885,690.00
SEC Filings
Recent regulatory filings
No filings found.
How much revenue does OSTX generate?
OS Therapies Incorporated (OSTX) reported $0.00 of revenue in fiscal 2025.
Is OSTX profitable?
OS Therapies Incorporated (OSTX) reported -$28,753,844.00 of net income.
Explore More
Continue the stock analysis
Jump to another research area for this company.